BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced that it will be showcasing its newly expanded ADME-Tox research capabilities at the 25th North American International Society for the Study of Xenobiotics (ISSX) Meeting, which will be held from September 10-13 in Boston, MA.
News
- Positive feedback from pre-IND meeting with FDA confirms Hikma’s continued development of AT307 under the 505(b)(2) regulatory pathway
- Abbreviated 505(b)(2) submission offers an efficient and streamlined development pathway with reduced risk
Read the September edition of eNews here, featuring:
► Welcome from Tony Jones, CEO
► What is the Importance of Training and Developing Your Workforce?
► Why is Working for a One Nucleus Member Company Good for You?
► Revitalising Conference Websites: Enhancing Engagement for Life Science Companies
► Are You Asking the Right Questions when Assessing Your Next Lab Space?
► New Horizons in Genetic Screening
One Nucleus and GTM Global Enter into Collaboration to Support Member International and Connectivity
One Nucleus and GTM Global Enter into Collaboration to Support Member International and Connectivity
Cambridge and London, UK, 05 September 2023
Sign up to receive the latest regulatory updates from Boyds: https://boydconsultants.com/sign-up/
In this month's newsletter they shared recent guidance and key updates from the regulatory agencies:
- Food and Drug Association (FDA)
- European Medicines Agency (EMA)
- Medicines and Healthcare products Regulatory Agency (MHRA)
- European Commission (EC)
- World Health Organisation (WHO)
More than half the Cambridge startups [60.7%] listed in Seedtable’s ‘Startups in Cambridge to Watch’ list last month [July 2023] have already appeared on cofinitive’s #21toWatch list in previous years.
This timely revelation, as the nominations window for #21toWatch 2024 opens, confirms that the #21toWatch awards really do spotlight the brightest and best from across Cambridge and beyond.
Check out and subscribe to the latest newsletter from Stevenage Bioscience Catalyst.
Highlights include:
In the latest edition of the Penningtons Manches Cooper LLP BioBrief newsletter, their team explores university-generated IP and in particular what it means for students who are involved and contributing to such IP...
Lab-on-chip technology for screening live tumor
Glasgow, UK based – ScreenIn3D reports on how their proprietary lab-on-a-chip technology is enabling cancer researchers to miniaturize their testing of biopsy tissue samples across a wide range of modalities and to test both single and combination drug therapies on live tissue samples.
Cambridge, UK, 30th August 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr. Tomasz Kostrzewski as Chief Scientific Officer. Previously Vice President of Science and Technology, Dr. Kostrzewski’s promotion creates a new position in CN Bio’s leadership team, marking another key milestone in the Company’s development as the fourth leadership-level appointment within the past year.